- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04213989
Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
An Investigator-initiated Study Assessing the Effect of Intermittent Pneumatic Compression (IPC) on Symptoms and Quality of Life in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema is a connective tissue disorder that affects up to 10% of women. It is characterized by painful, swollen subcutaneous tissue and disproportionate fat accumulation (primarily in the lower limbs, however it can spread to the abdomen and arms). Patients are often not aware they are affected by this disease; rather, they think they are just overweight or obese.
Patients with lipedema often feel frustrated and uncomfortable as symptoms such as heaviness, pain, and easy bruising impact quality of life. Affected limbs can become so large and heavy that daily tasks such as walking, cleaning, or shopping become impossible.
There is currently no cure for lipedema, thus treatment focuses on symptom management and improved patient-reported outcomes. At present, the two main courses of treatment include non-surgical conservative treatment (e.g., Comprehensive Decongestive Therapy (CDT), diet, exercise, emotional/psychological/social support) and lymph-sparing liposuction performed by a surgeon trained in lipedema treatment. The primary goals for treatment include: reduction/elimination of inflammation, swelling, and pain; increase in lymphatic flow, which reduces/eliminates excessive fluid and swelling; overall management of the physical impact of lipedema; and quality of life improvements which can include emotional, psychological/mental, spiritual, and social enhancement in addition to physical management.
Intermittent Pneumatic Compression (IPC) devices are often used as home-therapy to treat secondary lymphedema or lipo-lymphedema (lipedema with swelling) and may be helpful in preventing the progression of lipedema. IPC use moves lymphatic fluid and supports the elimination of proteinaceous fluids, thus leading to improved patient-reported symptoms, decreased limb girth and volume, increased elasticity of tissues, and fewer episodes of infection.
The purpose of this study is to assess whether 3-4 weeks of IPC usage is associated with alleviation of symptoms and improvement in quality of life in women with lipo-lymphedema (lipedema with swelling).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
O'Fallon, Missouri, United States, 63368
- Laser Lipo and Vein Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female age 18-70 years
- Stage 2-3 (Schmeller Type 2-3) lipedema with secondary lymphedema
- Willing and able to follow prescribed care for study period
- Able to access (via self-pay, patient assistance, or insurance programs) prescribed care within 60 days of Screening visit
Exclusion Criteria:
- BMI > 50
- Heart failure (acute pulmonary edema, decompensated acute heart failure)
- Pacemaker or implantable cardioverter defibrillator (ICD)
- Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)
- Severe peripheral artery disease (critical limb ischemia including ischemic rest pain, arterial wounds, or gangrene)
- Active skin or limb infection/inflammatory disease (acute cellulitis, other uncontrolled skin or untreated inflammatory skin disease) on the arms or trunk
- Active cancer (cancer that is currently under treatment, but not yet in remission)
- Poorly controlled kidney disease (glomerular filtration rate < 30 mls per minute), hypoproteinemia, pulmonary hypertension, hypothyroidism, cyclic edema, or Munchausen Syndrome
- Any circumstance where increased lymphatic or venous return is undesirable
- Currently pregnant or trying to become pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Conservative Care
Conservative care (may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT)
|
May include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
|
Experimental: Flexitouch Plus and Conservative Care
Flexitouch Plus with conservative care
|
A segmental, programmable, gradient advanced pneumatic compression device.
The system consists of a controller unit and garments, and provides in-home manual lymphatic drainage therapy in the legs for approximately 1 hour daily.
Conservative care may include 30-40 mmHg graduated compression up to waist, dietary counseling, exercise, and/or referral for CDT.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Circumferential Measurements Over Time
Time Frame: Changes between Screening and 3-4 weeks will be assessed
|
Tape measurements along both legs
|
Changes between Screening and 3-4 weeks will be assessed
|
Patient-Reported Quality of Life
Time Frame: Changes between Screening and 3-4 weeks will be assessed
|
RAND 36-Item Short Form Survey Instrument (SF-36) 1.0 is a global assessment of health impacts on quality of life that taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.
It also includes a single item that provides an indication of perceived change in health.
All items are scored so that a high score defines a more favorable health state.
In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.
|
Changes between Screening and 3-4 weeks will be assessed
|
Patient-Reported Pain Interference
Time Frame: Changes between Screening and 3-4 weeks will be assessed
|
PROMIS Item Bank v1.0 - Pain Interference - Short Form 6b is a 6 item survey that measures self-reported consequences of pain on relevant aspects of a person's life and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities.
All items are scored so that a low score is associated with less pain interference (a more favorable health state).
In addition, each item is scored on a 1 to 5 range so that the lowest and highest possible scores are 6 and 30, respectively.
|
Changes between Screening and 3-4 weeks will be assessed
|
Patient-Reported Pain
Time Frame: Changes between Screening and 3-4 weeks will be assessed
|
Wong Baker Faces Scale is a self-assessment tool that is easily understood by patients, so they are able to choose the face that best illustrates the physical pain they are experiencing associated with their lipo-lymphedema.
Face 0 doesn't hurt at all.
Face 2 hurts just a little bit.
Face 4 hurts a little bit more.
Face 6 hurts even more.
Face 8 hurts a whole lot.
Face 10 hurts as much as you can imagine, although you don't have to be crying to have this worst pain.
|
Changes between Screening and 3-4 weeks will be assessed
|
Patient-Reported Symptoms of Lipo-Lymphedema
Time Frame: Changes between Screening and 3-4 weeks will be assessed
|
NRS Symptom Survey is a 6-item survey that asks patients to rate their perceptions of swelling, heaviness, pain, fatigue, tenderness, and tightness independently for each leg using a 10-point numerical rating scale where 0 represents none/not present and 10 is worst imaginable.
All items are scored so that a low score is associated with fewer symptoms (defines a more favorable health state).
The lowest and highest possible scores per leg are 0 and 60, respectively, with a combined total score between 0 and 120.
|
Changes between Screening and 3-4 weeks will be assessed
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient-Reported Mobility
Time Frame: Changes between Screening and 3-4 weeks will be assessed
|
PROMIS Item Bank v2.0 - Mobility is a 15-item survey that focuses on activities of physical mobility such as getting out of bed or a chair to activities such as running.
All items are scored so that a high score is associated with more mobility (a more favorable health state).
In addition, each item is scored on a 5 to 1 range so that the highest and lowest possible scores are 75 and 15, respectively.
|
Changes between Screening and 3-4 weeks will be assessed
|
Change in Bioimpedance Measurements Over Time
Time Frame: Changes between Screening and 3-4 weeks will be assessed
|
InBody 770 whole body and segmental extracorporeal body weight / total body weight ratios
|
Changes between Screening and 3-4 weeks will be assessed
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas Wright, MD, Lakeview Medical Group, Inc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lipedema
-
Vanderbilt University Medical CenterRecruiting
-
Hautklinik DarmstadtThe Clinical Trials Centre CologneActive, not recruiting
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompleted
-
Primus PharmaceuticalsNortheastern UniversityCompleted
-
University Hospital Schleswig-HolsteinHanse-Klinik, Fachklinik für Liposuktion, Lübeck; Praxisklinik Kronshagen,...Recruiting
-
Haraldsplass Deaconess HospitalUniversity Hospital of North Norway; University of Bergen; St. Olavs Hospital; Sykehuset... and other collaboratorsRecruiting
-
Yuksek Ihtisas UniversityCompleted
-
Gazi UniversityCompleted
Clinical Trials on Conservative Care
-
MTI UniversityCompletedAmputation; Traumatic, Leg, LowerEgypt
-
Prof. Dr. Martin WabitschCharite University, Berlin, Germany; University of Leipzig; University of Witten... and other collaboratorsActive, not recruiting
-
Tactile MedicalTerminated
-
University of WashingtonCompletedEnd Stage Renal Disease | Patient Engagement | Dialysis | Decision Aid | End-of-life CareUnited States
-
Université du Québec à Trois-RivièresUnknownLateral EpicondylitisCanada
-
Austin HealthCompletedCritical IllnessAustralia
-
MTI UniversityRecruiting
-
Zimmer SpineZimmer BiometUnknown
-
VA Office of Research and DevelopmentRecruitingQuality of Life | Obstructive Sleep Apnea | Elderly | COPD | Sleepiness | Sleep Apnea Syndrome | Neurocognitive Function | Overlap Syndrome | Positive Airway PressureUnited States
-
Medtronic Spinal and BiologicsTerminatedLumbar Degenerative Disc DiseaseUnited States